- Home
- RHI vs JAZZ Comparison
RHI vs JAZZ Comparison
Compare RHI & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RHI
- JAZZ
- Stock Information
- Founded
- RHI 1948
- JAZZ 2003
- Country
- RHI United States
- JAZZ Ireland
- Employees
- RHI N/A
- JAZZ N/A
- Industry
- RHI Professional Services
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- RHI Consumer Discretionary
- JAZZ Health Care
- Exchange
- RHI Nasdaq
- JAZZ Nasdaq
- Market Cap
- RHI 7.9B
- JAZZ 7.3B
- IPO Year
- RHI N/A
- JAZZ 2007
- Fundamental
- Price
- RHI $70.92
- JAZZ $121.18
- Analyst Decision
- RHI Hold
- JAZZ Buy
- Analyst Count
- RHI 6
- JAZZ 14
- Target Price
- RHI $69.67
- JAZZ $173.93
- AVG Volume (30 Days)
- RHI 843.8K
- JAZZ 567.6K
- Earning Date
- RHI 01-28-2025
- JAZZ 02-26-2025
- Dividend Yield
- RHI 2.99%
- JAZZ N/A
- EPS Growth
- RHI N/A
- JAZZ 458.10
- EPS
- RHI 2.75
- JAZZ 7.04
- Revenue
- RHI $5,886,357,000.00
- JAZZ $3,992,712,000.00
- Revenue This Year
- RHI N/A
- JAZZ $7.51
- Revenue Next Year
- RHI $2.46
- JAZZ $6.84
- P/E Ratio
- RHI $25.79
- JAZZ $17.22
- Revenue Growth
- RHI N/A
- JAZZ 5.23
- 52 Week Low
- RHI $57.05
- JAZZ $99.06
- 52 Week High
- RHI $83.25
- JAZZ $134.17
- Technical
- Relative Strength Index (RSI)
- RHI 51.58
- JAZZ 46.66
- Support Level
- RHI $64.97
- JAZZ $118.72
- Resistance Level
- RHI $71.10
- JAZZ $124.66
- Average True Range (ATR)
- RHI 1.65
- JAZZ 2.82
- MACD
- RHI 0.24
- JAZZ -0.21
- Stochastic Oscillator
- RHI 81.06
- JAZZ 31.62
About RHI Robert Half Inc.
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates of its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry. The firm generates annual revenue of around $7 billion.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.